Diabetic Retinopathy – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Diabetic Retinopathy – Pipeline Review, H2 2019’, provides an overview of the Diabetic Retinopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy

– The report reviews pipeline therapeutics for Diabetic Retinopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Diabetic Retinopathy therapeutics and enlists all their major and minor projects

– The report assesses Diabetic Retinopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Diabetic Retinopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

A6 Pharmaceuticals

Accuitis Pharmaceuticals Inc

Acucela Inc

Adverum Biotechnologies Inc

Aerie Pharmaceuticals Inc

Akaal Pharma Pty Ltd

Antisense Therapeutics Ltd

Applied Therapeutics Inc

AptaBio Therapeutics Inc

Aptamer Sciences Inc

Araim Pharmaceuticals Inc

Ascentage Pharma Group International

BetaStem Therapeutics Inc

Bio-Thera Solutions Ltd

Boehringer Ingelheim International GmbH

Bonac Corp

CCRP Therapeutics GmbH

Cell Care Therapeutics Inc

Cell Medica Ltd

Charlesson LLC

Clayton Biotechnologies Inc

Coherus BioSciences Inc

Curacle Co Ltd

Dimerix Ltd

Elasmogen Ltd

Emerald Bioscience Inc

Ennovabio

Epigen Biosciences Inc

Everglades Biopharma LLC

F. Hoffmann-La Roche Ltd

Foresee Pharmaceuticals Co Ltd

Formycon AG

Generium

Glycadia Inc

Guangzhou Magpie Pharmaceutical Co Ltd

Hana Pharm Co Ltd

HanAll Biopharma Co Ltd

Hengenix Biotech Inc

iVeena LLC

Kato Pharmaceuticals Inc

Kodiak Sciences Inc

Kowa Co Ltd

Lupin Ltd

Luye Pharma Group Ltd

Mabion SA

Mirae Cell Bio Co Ltd

Mirrx Therapeutics A/S

Nanoscope Therapeutics Inc

NeuBase Therapeutics Inc

NeuMedics Inc

Neurodegeneration Therapeutics Inc

NGM Biopharmaceuticals Inc

Novelty Nobility Inc

OccuRx Pty Ltd

Ocugen Inc

OcuNexus Therapeutics Inc

OliPass Corporation

Opera Therapeutics

Oxurion NV

Palatin Technologies Inc

Panoptes Pharma GesmbH

Phanes Therapeutics Inc

PharmAbcine Inc

Profarma

Promedior Inc

Protheragen Inc

Regeneron Pharmaceuticals Inc

RegenxBio Inc

Retinset SL

Retrotope Inc

Rezolute Inc

Serodus ASA

Singh Biotechnology LLC

Skyran Biologics Inc

Stealth BioTherapeutics Corp

SunBio Inc

Sylentis SAU

Teraclon IDF SL

Translatum Medicus Inc

Valitor Inc

VESSL Therapeutics Ltd

Wntgen LLC

YD Life Science Co

Zih Yuan Tang Biotechnology Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Retinopathy Overview 6

Diabetic Retinopathy Therapeutics Development 7

Diabetic Retinopathy Therapeutics Assessment 18

Diabetic Retinopathy Companies Involved in Therapeutics Development 29

Diabetic Retinopathy Drug Profiles 46

Diabetic Retinopathy Dormant Projects 194

Diabetic Retinopathy Discontinued Products 198

Diabetic Retinopathy Product Development Milestones 199

Appendix 209

List of Tables

List of Tables

Number of Products under Development for Diabetic Retinopathy, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Diabetic Retinopathy – Pipeline by 3SBio Inc, H2 2019

Diabetic Retinopathy – Pipeline by A6 Pharmaceuticals, H2 2019

Diabetic Retinopathy – Pipeline by Accuitis Pharmaceuticals Inc, H2 2019

Diabetic Retinopathy – Pipeline by Acucela Inc, H2 2019

Diabetic Retinopathy – Pipeline by Adverum Biotechnologies Inc, H2 2019

Diabetic Retinopathy – Pipeline by Aerie Pharmaceuticals Inc, H2 2019

Diabetic Retinopathy – Pipeline by Akaal Pharma Pty Ltd, H2 2019

Diabetic Retinopathy – Pipeline by Antisense Therapeutics Ltd, H2 2019

Diabetic Retinopathy – Dormant Projects, H2 2019

Diabetic Retinopathy – Dormant Projects, H2 2019 (Contd..1), H2 2019

Diabetic Retinopathy – Dormant Projects, H2 2019 (Contd..2), H2 2019

Diabetic Retinopathy – Dormant Projects, H2 2019 (Contd..3), H2 2019

Diabetic Retinopathy – Dormant Projects, H2 2019 (Contd..4), H2 2019

Diabetic Retinopathy – Dormant Projects, H2 2019 (Contd..5), H2 2019

Diabetic Retinopathy – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Diabetic Retinopathy, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports